The establishment of novel diagnostic and prognostic maker using epigenetic changes in upper tract urothelial carcinoma
Not Applicable
Recruiting
- Conditions
- pper tract urothelial carcinoma
- Registration Number
- JPRN-UMIN000005439
- Lead Sponsor
- Keio University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Presence of active other cancers. 2.Having a severe complications occurred before this study; serious heart failure, renal failure, liver dysfunction, severe infection, and blood trouble
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cancer detection rate 3 and 5-year recurrence free rate 3 and 5-year cancer specific survival
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What epigenetic biomarkers are being evaluated for UTUC diagnosis in JPRN-UMIN000005439?
How do DNA methylation patterns in UTUC correlate with prognosis compared to traditional markers?
What histone modification targets are associated with UTUC progression in Keio University Hospital's study?
Are epigenetic changes in UTUC predictive of response to immune checkpoint inhibitors or chemotherapy?
What non-invasive epigenetic testing methods are explored for UTUC in this observational trial?